Noah Labs has been selected for the European Innovation Council (EIC) Accelerator program, securing up to €11 million in funding. This recognition highlights the company’s breakthrough voice-based diagnostics for heart failure and marks an important step in advancing its AI-driven cardiovascular care platform.

Adesso Ventures, the German Heart Center Berlin Foundation, the Brandenburg Investment Bank, and Business Angels are participating in the funding round. Noah Labs' flagship software, Ark, enables AI-powered telemonitoring of heart failure patients. Additionally, Noah Labs is leading three clinical studies on the effectiveness of voice analysis as a novel biomarker for detecting heart failure.

Noah Labs is thrilled to announce that our telemonitoring software, Noah Labs Ark, has secured Class IIa medical device approval under the European Union Medical Device Regulation (MDR), paving the way for advanced cardiovascular diseases management.

Endowed with a €1.5 million grant from the European Institute of Innovation and Technology (EIT), the PRE-DETECT-HF project officially kicked off on 1 January, 2024. The grant will fund a ground-breaking clinical trial that aims to utilise AI-powered speech analysis for the early detection and treatment of heart failure.

The German Heart Center Berlin (DHZB) Foundation and Noah Labs have entered a strategic collaboration and investment agreement to develop breakthrough voice-based biomarkers for heart failure. The collaboration is in the field of diagnostics and monitoring of cardiovascular diseases. It includes joint clinical research and development, as well as an investment in the company.

Noah Labs is pleased to announce that we have achieved ISO 13485 certification as a medical device manufacturer. This is a testament to our commitment to quality and excellence in all of our product offerings.